Skip to main content

Design Therapeutics Stock Forecast, Price & News

-2.15 (-8.15 %)
(As of 05/12/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume24,349 shs
Average Volume175,361 shs
Market Capitalization$1.30 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive DSGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Design Therapeutics

Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.


See More Headlines

Industry, Sector and Symbol

Industry --
Current SymbolNASDAQ:DSGN
Phone858 293 4900
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Market Cap$1.30 billion
Next Earnings Date8/9/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.33 out of 5 stars

-- Sector

12th out of 280 stocks

-- Industry

12th out of 282 stocks

Analyst Opinion: 3.3Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Design Therapeutics (NASDAQ:DSGN) Frequently Asked Questions

Is Design Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Design Therapeutics stock.
View analyst ratings for Design Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Design Therapeutics?

Wall Street analysts have given Design Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Design Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Design Therapeutics' next earnings date?

Design Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Design Therapeutics

What price target have analysts set for DSGN?

3 analysts have issued 1-year target prices for Design Therapeutics' shares. Their forecasts range from $28.00 to $42.00. On average, they anticipate Design Therapeutics' share price to reach $35.33 in the next year. This suggests a possible upside of 45.8% from the stock's current price.
View analysts' price targets for Design Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Design Therapeutics' key executives?

Design Therapeutics' management team includes the following people:
  • Dr. João Siffert, Pres, CEO & Director (Age 58)
  • Dr. Sean Jeffries Ph.D., Chief Operating Officer (Age 41)

Who are some of Design Therapeutics' key competitors?

When did Design Therapeutics IPO?

(DSGN) raised $228 million in an IPO on Friday, March 26th 2021. The company issued 12,000,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

What is Design Therapeutics' stock symbol?

Design Therapeutics trades on the NASDAQ under the ticker symbol "DSGN."

When did the company's quiet period expire?

Design Therapeutics' quiet period expired on Wednesday, May 5th. Design Therapeutics had issued 12,000,000 shares in its IPO on March 26th. The total size of the offering was $240,000,000 based on an initial share price of $20.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are Design Therapeutics' major shareholders?

Design Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Ensign Peak Advisors Inc (0.09%) and Geode Capital Management LLC (0.07%).

Which institutional investors are buying Design Therapeutics stock?

DSGN stock was purchased by a variety of institutional investors in the last quarter, including Ensign Peak Advisors Inc, and Geode Capital Management LLC.

How do I buy shares of Design Therapeutics?

Shares of DSGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Design Therapeutics' stock price today?

One share of DSGN stock can currently be purchased for approximately $24.23.

How much money does Design Therapeutics make?

Design Therapeutics has a market capitalization of $1.30 billion.

How many employees does Design Therapeutics have?

Design Therapeutics employs 15 workers across the globe.

What is Design Therapeutics' official website?

The official website for Design Therapeutics is

How can I contact Design Therapeutics?

The company can be reached via phone at 858 293 4900.

This page was last updated on 5/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.